Universal Health Coverage (UHC) is grounded in the principle that the highest attainable standard of physical and mental health is a fundamental human right. It is a longstanding tenet of global health and has, in recent years, become the overarching framework for policies and investments in health globally and nationally (figure 1). Enshrined as Sustainable Development Goal 3.8 (SDG), UHC has been adopted as a standalone global commitment and a mechanism to make progress across a suite of other SDGs, including the elimination of poverty, education, gender equality, decent work and economic growth 1 .
Since 2000, there have been substantial improvements in the coverage of essential health services globally; however, the growing burden of non-communicable diseases (NCDs), including cancer, means that no country can yet claim to have fully achieved UHC 2 . As such, there is a clear need for all governments to scale-up action and investments in health to deliver UHC by 2030. This brief provides cancer advocates with a short introduction to UHC, the high-level links with cancer control and explores the opportunities to advocate for cancer within UHC plans drawing on examples from UICC members.
UN High-level Meeting on UHC
The first United Nations (UN) High-Level Meeting on UHC was held in New York on the 23rd September 2019. It brought together political leaders from around the world to mobilise political support and commit to achieving UHC. The resulting Political Declaration does not focus on individual diseases, instead it sets out a framework for countries to build the robust health systems necessary for UHC.
Read UICC's digest of the Declaration.
What is Universal Health Coverage?
A 2019 World Health Organization (WHO) report identified that at least 50% of the world's population still do not have full coverage of essential health services, while around 100 million people are pushed into extreme poverty as a result of paying out-of-pocket for care 3 .
Central to UHC is the recognition that "the enjoyment of the highest attainable standard of [physical and mental] health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition" 4 . The focus on the right to health is driving calls for governments and other stakeholders to ensure that UHC planning and implementation prioritises the needs of the most vulnerable, poor and underserved first, in order to address longstanding barriers to accessing essential health services.
Recognising this, the objectives of UHC are to ensure:
1. Equitable access -access to a service should be determined by need, regardless of a person's ability to pay 2. Quality care -services available should promote or improve the health of those using them 3. Financial risk-protection -UHC must include mechanisms to protect against financial risks so that people using health services are not pushed into poverty.
Given the current state of many national health systems, all stakeholders recognise that achieving UHC must be realistic, leading WHO and others to champion the progressive realisation of UHC. This entails countries making coordinated investments and policies to scale up the three 'dimensions' of population coverage, service provision and financial protection by 2030 (figure two) 5 . 
UHC and cancer
Globally, cancer is the second leading cause of mortality, morbidity and disability, with an estimated 18.1 million new cases and 9.6 million deaths in 2018 6 . In nearly every country, the cancer burden and mortality are rising, with the highest increases in lowand middle-income countries (LMICs), which now account for approximately 70% of all cancer deaths 7 .
The burden of cancer is already having a profound impact across all three dimensions of UHC. Access to essential cancer services is characterised by significant inequalities, both globally and nationally. It is estimated that 90% of high-income countries can provide access to the essential treatment modalities (surgery, radiotherapy, and essential medicines) for cancer patients, compared to 30% of LMICs 7 . This results in striking international disparities in cancer patient outcomes.
Access to radiotherapy illustrates these divides. While around 80% of cancer patients live in LMICs, these individuals are only served by approximately 5% of global radiotherapy resources 8 . In practical terms, this means that more than 90% of cancer patients in low-income countries lack access, despite radiotherapy being recommended for around 52% of cancer patients 9 . Studies further show similar disparities exist within countries and, given the drive for health equity, addressing these disparities will be an important focus within the progressive realisation of UHC.
Even where patients can physically access services, the costs associated with their use may prohibit patients from seeking care. For example, in Malaysia, the costs of accessing colorectal cancer treatment forced nearly 48% of patients' families into catastrophic health spending 10 . Similar national-level studies reaffirm that the costs of accessing cancer treatment and care poses a significant financial risk, both to national health systems and patients and their families 11 .
Globally, the most recent data suggest that the estimated annual economic cost of cancer has already reached US$ 
Figure 2
Laying the foundations for UHC With the adoption of the 2019 UN Political Declaration on UHC, governments are shifting their focus from exploring what UHC is and why to pursue it, to understanding how UHC can be achieved within their national context. All countries will need to compile and understand national data on cancer in order to development a comprehensive national UHC plan and prioritise interventions to develop a package of core UHC services.
Delivering UHC cannot be a one-size-fits-all approach, not is UHC a static end point for health systems. Countries will need to continuously review and revise national UHC packages in light of economic, epidemiological and health system changes. The journey to UHC will, however, contain a number of common steps.
The process of developing UHC plans and packages provide cancer and NCD advocates with several opportunities to make the case for the integration of essential services. Figure three , below, provides an overview of these stages and key aspects policy makers and advocates should consider. Stages in the development of national UHC plans and packages
Identifying interventions

Availablility of interventions
Understanding the national context and identifying inequities
The first stage in UHC development should be a comprehensive assessment of national health needs and system capacities. While UHC seeks to guarantee access to essential services, stakeholders must recognise that UHC cannot provide access to all possible health interventions regardless of health benefits or added value, nor is there a one-size-fitsall approach 3 . Achieving UHC requires governments to identify a priority set of services and interventions that can be implemented for the whole population, delivered to a high quality, and covered by financial protection mechanisms.
Prioritising UHC packages should include a critical assessment of the national cancer control landscape using accurate and quality data. Strong national health information systems, including populationbased cancer registries (PBCRs), are a primary source of this data. The process of selecting priority cancer interventions will vary greatly by country, but should draw on key information including:
• Underserved groups -UHC planners need to understand which groups are currently underserved by health systems and those that are most vulnerable to catastrophic health spending. PBCRs can be an important source of data here, as they can help identify differences in the burden of disease and treatment outcomes across different geographies as well as social, economic and cultural groups.
• National disease burden data -understanding which cancers account for the greatest morbidity, mortality and health spending nationally is essential. It is also important to track how the national cancer burden is changing over time to provide a foundation for comprehensive cancer control planning through to 2030 and beyond.
• National health goals -Planners and policy makers should identify existing plans or strategies that provide a foundation for developing UHC strategies. For cancer advocates, a national cancer control plan (NCCP) is a key advocacy resource to help identify priority national disease types, interventions and budgetary requirements.
The UHC planning process provides an opportunity for cancer advocates to spotlight where and how cancer patients are at risk of being 'left behind' in their national health system. In many LMICs, investments in cancer have been limited by misconceptions that cancer is too complex or costly to address effectively, particularly where there is strong public and political focus on communicable disease programmes.
Engaging patients and clinicians in advocacy can be very powerful in this context, as they are able to voice the needs of patients and communities at risk of being left behind.
Identifying and prioritising cost-effective interventions
Over time, UHC service packages will need to evolve to respond to epidemiological changes and developments in health systems. Decision-makers will need to continually review national disease burden data, expenditure and equity tracer indicators to refine and expand national packages to meet the needs of the population. Throughout this process it is important to consider:
• Interventions to address priority national cancers -drawing on disease burden data, the prioritisation process should consider interventions for priority national disease types from across the cancer control spectrum, including primary prevention, early detection and diagnosis, treatment, survivorship and palliative care.
• Impacts on equity nationally -effectively addressing cancer and other NCDs will require an integrated approach with other health services. Particular attention should be paid to reducing inequalities in coverage of cancer prevention programmes (such as vaccination and tobacco control programmes), access to cancer early detection, quality treatment and care, as well as monitoring out-of-pocket spending for cancer and its impact.
• Acceptability and demand -significant disparities exist in cancer incidence and survival across and within countries. The social determinants of cancer have largely focused on exposure to risk factors; however, they also have significant implications for patients' ability and willingness to access essential services. For example, women in Colombia with lower levels of education are five-times more likely to die of cervical cancer, compared to women with highlevel education 14 . The development of UHC plans and service packages will need to acknowledge and address these existing socio-economic and cultural barriers. Cost-effectiveness studies have an important role in planning for UHC. The principle behind cost-effectiveness analyses is to provide decision-makers with information on the best value investments by estimating the costs and health gains of alternative interventions. Its goal is to support decision-makers in selecting and prioritising the allocation of resources.
However cost-effective analyses should not be the sole basis for decision-making to select interventions for the prevention and control of NCDs, including cancer. Effectiveness, budget impact, safety, feasibility of service delivery, relevance, acceptability and equity should all be considered in the development of UHC service packages and this information is also key to 'real world' decision making by national governments, alongside development indicators and resource levels.
Implementation planning
The ability to effectively roll-out services is likely to shape in large part which interventions decisionmakers include within UHC packages. As such, it is useful for cancer advocates to understand and recognise the demands that proposed interventions will have on health systems including:
• Policy and legislation requirements -several of the interventions included in figure four require supporting policy or legislation changes in order to be effective. These can include increased taxation of unhealthy products such as tobacco, alcohol or sugar-sweetened beverages, or reforms to improve access to controlled medicines for pain relief. International and country success stories provide powerful resources to support advocacy for these measures.
• Health system infrastructure -UHC discussions have focused largely on the role of primary health care (PHC) and the use of a PHC-approach as a framework for investing in health systems and building capacities to deliver UHC sustainably.
Since the Alma-Ata Declaration, PHC has been considered the cornerstone of health for all 3 as it is the entry point for most patients to the health system and the recent Astana Declaration re-emphasised the link between PHC and UHC. While a sole focus on PHC would limit effective cancer control nationally, the PHC approach set out in the Declaration provides a robust framework to advocate for the progressive realisation of cancer services, including strengthening referral networks to multimodal treatment, including investments in more complex interventions like surgery and radiotherapy which have largely been missing to date.
• Human resources for health -developing the human resources required for comprehensive cancer prevention and management is a longterm process, but must be an essential part of UHC planning. The training of specialist staff through the development of national, regional and global curricula and their retention (including adequate remuneration and continuous education), will be critical to achieving UHC. This should leverage existing international and regional programmes, such as those provided by the Global Initiative for Cancer Registries, and integrating these into sustainable national strategies to strengthen knowledge transfer and the skills of on human resources for health.
• Financial demands -all national UHC packages will be limited to some extent by the costs of interventions. For cancer advocates, persistent misconceptions that cancer services are too expensive, particularly in LMICs may limit the willingness to act. In response, it will be essential to marshal the evidence on the cost-effectiveness of essential cancer services. For example, implementing a basic package of palliative care could be achieved for an investment of US$3 per person in LMICs 15 , while investments in developing radiotherapy facilities in LMICs could be recouped within 10 to 15 years in LMICs and has the potential to save 26.9 million life years 16 . 
Monitoring and evaluating impact
The final stage of UHC development should focus on the monitoring and evaluation of national plans and packages. Monitoring and evaluating the impact of UHC will be an iterative process and, over the course of UHC planning and implementation, key elements should be considered including:
• Targets and indicators -many governments are currently identifying which UHC metrics (population coverage, package size, financial protection) will be undertaken initially as part of the progressive realisation of UHC in the medium-to long-term. Thus, accelerated action for cancer will look different in each country in response to different health system capacities, but each country should have clear and measurable targets and indicators to track progress and report back periodically.
• Multistakeholder engagement -the input of civil society groups (including patients, clinicians and community groups) should be a core component of the development of UHC policy goals, benefit packages, and monitoring and evaluation in order to ensure that services are most effectively responding to patient needs. In this respect, it is important for governments to establish multistakeholder mechanisms to engage different stakeholders to elicit input and safeguard the transparency of the UHC development process.
Driving change
Countries around the world have already begun to take action to achieve UHC. Included below are several short case studies on how advocates from across the cancer control community are working to drive change. The team also worked with partners in the NCD Alliance of Kenya (NCDAK) to coordinate a roundtable discussion in early 2019 on opportunities to integrate core services for cancer and other NCDs, including HPV vaccination, improving public health education and early detection. The report from this roundtable was disseminated by NCDAK and counterparts in the Ministry of Health to seven counties and healthcare providers to help shape their UHC implementation process.
The current Kenyan UHC pilot package includes full coverage of medicines on the national essential medicines list for cancer and palliative care, and access to radiotherapy (in Nairobi) and surgery is covered under the expanded National Hospital Insurance Fund. The pilot period will end in October 2019 after which the government will conduct a review to shape the national UHC package.
Read the full case study here.
Philippines: leveraging legislation to bring cancer control to scale
The journey to UHC in the Philippines began with the implementation of a 'Medicare' health insurance in 1971. In 1995, the National Health Insurance Act paved the way for the creation of the Philippine Health Insurance Corporation which manages PhilHealth and was enacted to provide social health insurance coverage for all Filipinos. While coverage had increased to 82% by 2009, conditions that resulted in prolonged hospitalisation and medical care still posed major financial hardship.
In response to civil society pressure, PhilHealth introduced the 'Z benefits' package which covered care for breast, prostate, cervical and childhood cancer (Acute Lymphocytic Leukaemia) and in 2015, colon and rectum cancers were added. In February 2019, the Government of the Philippines passed a UHC law to reform and strengthen the health care system so all Filipinos will receive the health care they need, when they need it, without suffering undue financial difficulties. The focus of the law was twofold: to provide automatic coverage of all Filipinos in PhilHealth and to strengthen the national integrated care network (encompassing both service delivery systems and financial protection mechanisms) across both public and private facilities.
In the same month, the National Integrated Cancer Control Act was also passed into law in recognition of the complexity of cancer care and the urgent need to prepare for a projected increase of 80% in cancer incidence by 2030. This law provides a guiding framework for integrated cancer control activities and comprehensive services in the cancer continuum of care, for all cancers and for all ages. Cancer is the third leading cause of morbidity and mortality in the Philippines and continues to be a major source of catastrophic out-of-pocket spending of between 50-70%.
Throughout the development and legislative processes of these laws, civil society organisations were actively involved in driving the advocacy initiatives and creating a supportive environment. UICC members Philippine Cancer Society, Cancer Warriors Foundation and I Can Serve were founding members of the Cancer Coalition which served as the convenor of dialogues with other key stakeholders: legislators, government, private sector, cancer patient support organisations and professional societies, to promote the rights and needs of adult and paediatric cancer patients and survivors. Throughout this process, advocates adopted a 'collect, connect' strategy which continuously gathered information, perspectives and partners to sustain momentum and build consensus on priorities for cancer control and cancer care pathways in the country. This was essential to build a unified cancer community voice and ensure a strong sense of ownership of the law as a pre-requisite for successful implementation of the Act's provisions.
Malaysia: Scaling up self-sampling cervical cancer screening
Since 2010, Malaysia has been conducting a national HPV vaccination programme which has been very successful, covering between 83% and 91% of the target population each year 19 . While this will reduce the long-term burden of cervical cancer, it was noted that participation in the national opportunistic screening programme remained low with long-term implications for the stage at which women are being diagnosed. There were clear opportunities for an overhaul of the cervical screening program to reduce the impact of a preventable cancer nationally.
The adoption of a national 'standard' cervical cancer screening programme adapted from high-income countries did not work, as Malaysia lacked the infrastructure and human resources to implement it in full. In 2017, the Ministry of Health was starting to review and consider changes to the existing cervical cancer screening offer, including a formal commitment to implement HPV DNA testing in the updated NCCP. Around the same time, research undertaken at the University of Malaya found that self-sampling was effective and acceptable to women and presented an alternative model.
The team worked closely with the Ministry to make the case for self-sampling, engaging extensively with the Family Development and Primary Health Care Sectors within the Ministry as their collaboration would be critical to the success of any self-sampling program. The result was Project Rose, which piloted self-sampling in government-run health clinics across Malaysia. This was achieved with technical support from experts at VCS Foundation Ltd. who had conducted similar programmes in other countries. This led to the launch of the Rose Foundation with the focus of continuing to support cervical cancer screening, especially in rural areas, in Malaysia by working closely with stakeholders.
